Sign in

You're signed outSign in or to get full access.

NI

NeueHealth, Inc. (NEUE)·Q3 2024 Earnings Summary

Executive Summary

  • Q3 2024 was NeueHealth’s strongest quarter to date on adjusted EBITDA, delivering $9.4M, with consolidated revenue of $232.9M and gross margin improvement versus prior year; management reaffirmed full-year guidance and highlighted momentum into 2025 .
  • Segment mix was favorable: NeueCare generated $83.9M revenue and $16.4M operating income, while NeueSolutions produced $152.0M revenue and a $(5.8)M operating loss with medical costs “moderately lower” than expectations .
  • KPIs showed breadth: approximately 509,000 consumers served, above the full-year range, including ~347,000 value-based clinic consumers, ~119,000 enablement consumers, and ~43,000 Medicare beneficiaries in ACO REACH; year-over-year, value-based consumers rose to 390,000 and enablement lives to 119,000 .
  • Guidance was maintained: FY2024 revenue ≈ $950M, adjusted operating cost ratio 15–16% ex-corporate (19–20% including corporate), and adjusted EBITDA $15–$25M; management expects to finish at the low end of adjusted operating cost ratio and the high end of consumer ranges .
  • Potential stock catalysts: confirmation of multi-quarter adjusted EBITDA profitability, reinforced growth narrative into 2025, and strategic simplification via full ownership of Centrum Health announced Oct 30, 2024 .

What Went Well and What Went Wrong

What Went Well

  • “We have delivered Adjusted EBITDA profitability for three consecutive quarters” and achieved $9.4M in Q3, positioning the company within its $15–$25M full-year target through the first three quarters .
  • NeueCare outperformed with $83.9M revenue and $16.4M operating income; provider enablement consumers grew to ~119,000, exceeding expectations and contributing to strong segment revenue .
  • Year-over-year gross margin improved to 21.6% (vs. 16.0% in Q3’23), reflecting focus on long-term profitable growth and operating discipline .

What Went Wrong

  • Revenue declined year-over-year to $232.9M (from $269.4M in Q3’23), driven primarily by lower ACO REACH revenue and continued ACA wind-down dynamics .
  • GAAP net loss remained significant at $(40.4)M, with diluted loss per share from continuing operations of $(6.78); NeueSolutions posted a $(5.8)M operating loss .
  • ACA insurance business wind-down persists, with ~$123M cash reserved for remaining medical costs and wind-down expenses, and continued capital retrieval and liability reduction; restricted cash/investments totaled $42.5M within nonregulated cash .

Financial Results

MetricQ1 2024Q2 2024Q3 2024
Revenue ($USD Millions)$245.095 $225.991 $232.933
Diluted EPS – Continuing Ops ($USD)$(2.31) $(6.42) $(6.78)
Adjusted EBITDA ($USD Millions)$2.529 $3.962 $9.396
Operating Cost Ratio (GAAP, %)27.3% 31.1% 27.5%

Notes:

  • Estimates comparison: Wall Street consensus via S&P Global was unavailable due to daily request limits; estimates not provided.

Segment breakdown (Q3 2024 vs Q3 2023):

SegmentQ3 2023 Revenue ($USD M)Q3 2024 Revenue ($USD M)Q3 2023 Operating Income (Loss) ($USD M)Q3 2024 Operating Income (Loss) ($USD M)
NeueCare$67.134 $83.867 $(390.761) $16.430
NeueSolutions$200.777 $152.043 $(29.355) $(5.832)

KPIs:

KPIQ3 2023Q3 2024
Value-Based Consumers served355,000 390,000
Enablement Services Lives31,000 119,000
Total Consumers Served—~509,000
Value-Based Clinic Consumers—~347,000
ACO REACH Beneficiaries—~43,000

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Total RevenueFY 2024≈ $950M (reaffirmed) ≈ $950M Maintained
NeueCare RevenueFY 2024≈ $320M (reaffirmed) ≈ $320M Maintained
NeueSolutions RevenueFY 2024≈ $640M (reaffirmed) ≈ $640M Maintained
Adjusted Operating Cost Ratio (ex-corporate)FY 202415%–16% 15%–16% Maintained; expecting low end including corporate
Adjusted Operating Cost Ratio (incl. corporate)FY 202419%–20% 19%–20% Maintained; expecting low end
Adjusted EBITDAFY 2024$15M–$25M $15M–$25M Maintained
Consumers Served (Enterprise)FY 2024475k–500k 475k–500k Maintained; tracking at/above high end
Value-Based Clinic ConsumersFY 2024330k–345k 330k–345k Maintained; expecting high end
NeueSolutions Consumers (incl. ACO REACH)FY 2024145k–155k 145k–155k Maintained; expecting high end
ACO REACH ConsumersFY 2024≈ 45k ≈ 45k Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 2024 and Q2 2024)Current Period (Q3 2024)Trend
ACO REACH dynamicsQ1/Q2: Lower aligned beneficiaries drove YoY ACO REACH revenue declines; medical costs down with lower beneficiaries Served ~43k beneficiaries; care management initiatives ongoing; medical costs moderately lower Stabilizing operationally; volume lower YoY but improving cost discipline
Provider enablement growthQ1: Segment revenue $173.9M; modest operating loss ; Q2: enablement consumers rising Enablement consumers ~119k, exceeded expectations; strong revenue contribution Accelerating growth
Care delivery (NeueCare)Q1/Q2: Capitated revenue growth; mixed operating results with impairment in Q2 $83.9M revenue; $16.4M operating income; value-based clinic consumers ~347k Strengthening profitability
ACA insurance wind-downQ1/Q2: large operating cash flow swings; liability reduction; balance sheet actions ~$123M cash for remaining costs; liabilities continue to decline; nonregulated cash/short-term investments $119.2M incl. $42.5M restricted Progressing; liquidity ring-fenced for wind-down
Geographic/partner expansionPrior: Central Florida footprint expansion via payer relationships Reinforced payer partnerships and capital-efficient growth strategy; full ownership of Centrum Health simplifies operations Positive, simplification and scale enablement

Management Commentary

  • CEO: “We have delivered Adjusted EBITDA profitability for three consecutive quarters, and we believe we are well-positioned to finish 2024 on a strong note… we see significant opportunities to build on our success in 2025 and beyond” .
  • CEO on strategy: Focus on diversifying consumer base across ACA, Medicare, Medicaid; grow capital-efficiently leveraging payer relationships; expand provider partnerships and CMS programs (ACO REACH/MSSP) .
  • CEO update: Acquired full ownership of Centrum Health to simplify corporate structure and streamline operations .
  • CFO: “NeueHealth consolidated revenue for the third quarter was $232.9 million with gross margin of $50.2 million… adjusted EBITDA of $9.4 million… best quarterly financial performance” .
  • CFO outlook: Confirmed FY revenue ≈ $950M, adjusted EBITDA $15–$25M, adjusted operating cost ratio 15–16% ex-corporate (19–20% incl. corporate); expects low end of cost ratio and high end of consumer ranges .

Q&A Highlights

  • The provided transcript comprises prepared remarks and did not include a separate Q&A section; key clarifications were embedded in management’s commentary on ACA wind-down liquidity, consumer ranges, and segment expectations .

Estimates Context

  • Wall Street consensus estimates (S&P Global) for Q3 2024 revenue and EPS were unavailable due to daily request limits; as a result, comparisons vs consensus cannot be provided at this time. Values would normally be retrieved from S&P Global.

Key Takeaways for Investors

  • Three consecutive quarters of adjusted EBITDA profitability culminating in a $9.4M print in Q3 underscores improving unit economics and operating discipline; this remains a near-term narrative driver .
  • Segment divergence continues: NeueCare is profit center ($16.4M operating income), while NeueSolutions’ loss narrowed to $(5.8)M; mix shift and enablement growth should support margin trajectory .
  • Gross margin expansion (21.6% vs. 16.0% YoY) suggests pricing/cost discipline and portfolio focus; supports the maintained full-year guidance .
  • Consumer growth breadth (≈509k total) and enablement scaling (~119k) provide volume underpinning; achieving or exceeding high-end consumer guidance is plausible per management .
  • ACA wind-down execution and liquidity ring-fencing ($123M for remaining costs; nonregulated cash/short-term investments $119.2M incl. $42.5M restricted) reduce tail risk into 2025 .
  • Strategic simplification via full ownership of Centrum Health should improve operational control and alignment ahead of expansion efforts; potential medium-term multiple catalyst if synergy capture is evidenced .
  • With guidance reaffirmed and momentum cited into 2025, monitoring ACO REACH volumes, enablement consumer additions, and adjusted operating cost ratio at quarter-end (low end targeted) will be key for near-term trading setups .